iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Up 428.3% in January

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 6,747 shares, a growth of 428.3% from the December 31st total of 1,277 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 40,604 shares, the short-interest ratio is presently 0.2 days. Based on an average trading volume of 40,604 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.

iShares Genomics Immunology and Healthcare ETF Trading Up 0.7%

Shares of IDNA stock opened at $29.65 on Wednesday. The firm has a market capitalization of $148.25 million, a price-to-earnings ratio of 14.76 and a beta of 1.07. The business’s 50-day moving average price is $27.19 and its 200-day moving average price is $24.67. iShares Genomics Immunology and Healthcare ETF has a 12 month low of $17.26 and a 12 month high of $30.30.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

Several large investors have recently modified their holdings of IDNA. Portland Global Advisors LLC raised its position in shares of iShares Genomics Immunology and Healthcare ETF by 0.7% in the 3rd quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock worth $2,432,000 after acquiring an additional 684 shares in the last quarter. Triumph Capital Management acquired a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 3rd quarter worth approximately $35,000. Ameriprise Financial Inc. lifted its position in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock valued at $1,688,000 after acquiring an additional 5,540 shares during the period. Finally, Flow Traders U.S. LLC bought a new position in iShares Genomics Immunology and Healthcare ETF during the second quarter worth $931,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.